← Back to Search

Behavioural Intervention

Peer Support for Polysubstance Abuse (PRISM Trial)

N/A

Recruiting

Led By Jessica F Magidson, PhD

Research Sponsored by University of Maryland, College Park

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured over 12 months

Awards & highlights

PRISM Trial Summary

This trial will test a peer-led intervention to help opioid use disorder patients in an underserved, rural area adhere to medication and reduce polysubstance use.

Who is the study for?

This trial is for adults over 18 with opioid use disorder and polysubstance use in a rural area, who have struggled to stick to their medication plan or haven't refilled their pharmacy prescription recently. It's not for those with untreated severe mental health issues or pregnant individuals.Check my eligibility

What is being tested?

The study tests 'Peer Activate,' a peer-led program aiming to improve adherence to opioid addiction medications and reduce the use of multiple substances. Participants will either receive this new intervention or the usual treatment, and they'll be followed for twelve months.See study design

What are the potential side effects?

Since 'Peer Activate' involves behavioral support rather than medication, side effects are minimal compared to drug treatments. However, participants may experience emotional discomfort when discussing substance use habits.

PRISM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured from baseline to 12-month follow-up.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured from baseline to 12-month follow-up.

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured from baseline to 12-month follow-up. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Six-Month Polysubstance Use Self Report

Six-Month Polysubstance Use Urinalysis

Secondary outcome measures

Intervention Fidelity

Intervention Session Attendance

Intervention Uptake

+4 more

Other outcome measures

Overdose risk

Six-month Criminal and Legal Activities

Six-month Health-related Quality of Life

+15 more

PRISM Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Peer-Delivered Behavioral Activation ("Peer Activate")Experimental Treatment1 Intervention

Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention and reduce polysubstance use.

Group II: Treatment As UsualActive Control1 Intervention

Participants in the TAU group will receive enhanced treatment as usual, defined as MTU services as usual enhanced with additional community referrals and follow-ups on those referrals, in addition to regular meetings with an addiction medicine physician and PRS on the MTU. Standard PRS contact typically includes connection to local resources and general peer support as needed.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreOTHER

688 Previous Clinical Trials

374,476 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,551 Total Patients Enrolled

Weill Medical College of Cornell UniversityOTHER

1,055 Previous Clinical Trials

1,316,115 Total Patients Enrolled

Media Library

Peer-Delivered Behavioral Activation (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05973838 — N/A

Treatment Compliance Research Study Groups: Peer-Delivered Behavioral Activation ("Peer Activate"), Treatment As Usual

Treatment Compliance Clinical Trial 2023: Peer-Delivered Behavioral Activation Highlights & Side Effects. Trial Name: NCT05973838 — N/A

Peer-Delivered Behavioral Activation (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05973838 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still space for participants in this clinical experimentation?

"According to clinicaltrials.gov, this trial is currently recruiting patients as of July 25th 2023 - the most recent edit was made on that date since its initial posting on June 15th 2023."

Answered by AI

To what extent is the patient sample size for this experiment?

"Affirmative, based on the clinicaltrials.gov data available this medical research is currently accepting participants. It was initially posted on June 15th 2023 before being edited lastly on July 25th 2023 and requires 180 individuals to enroll from 3 sites."

Answered by AI

What are the key aims of this clinical experiment?

"The primary outcome of this trial, measured over a 6-month period from intake onwards, is Polysubstance Use Urinalysis. Secondary outcomes include Six-Month Problems Associated with Substance Use (assessed using the Short Inventory of Problems), Six-month Buprenorphine Adherence (calculated by urinalysis testing for multiple drugs and metabolites), Continuity of pharmacy for Medication Assisted Opioid Use Disorder through six months, and Intervention Uptake (measured as the % who agree to participate)."

Answered by AI

Recent research and studies

Addictive BehaviorsJournal

Examining the Effect of the Life Enhancement Treatment for Substance Use (LETS ACT) on Residential Substance Abuse Treatment Retention

Magidson, Jessica F., Stephanie M. Gorka, Laura MacPherson, Derek R. Hopko, Carlos Blanco, C.W. Lejuez, and Stacey B. Daughters. 2011. “Examining the Effect of the Life Enhancement Treatment for Substance Use (LETS ACT) on Residential Substance Abuse Treatment Retention”. Addictive Behaviors. Elsevier BV. doi:10.1016/j.addbeh.2011.01.016.

AIDS Patient Care and STDsJournal

A Pilot Trial of Integrated Behavioral Activation and Sexual Risk Reduction Counseling for Hiv-uninfected Men Who Have Sex with Men Abusing Crystal Methamphetamine

Mimiaga, Matthew J., Sari L. Reisner, David W. Pantalone, Conall O'Cleirigh, Kenneth H. Mayer, and Steven A. Safren. 2012. “A Pilot Trial of Integrated Behavioral Activation and Sexual Risk Reduction Counseling for Hiv-uninfected Men Who Have Sex with Men Abusing Crystal Methamphetamine”. AIDS Patient Care and Stds. Mary Ann Liebert Inc. doi:10.1089/apc.2012.0216.

AddictionJournal

The Effect of a Behavioral Activation Treatment for Substance Use on Post-treatment Abstinence: A Randomized Controlled Trial

Daughters, Stacey B., Jessica F. Magidson, Deepika Anand, C. J. Seitz-Brown, Yun Chen, and Sydney Baker. 2017. “The Effect of a Behavioral Activation Treatment for Substance Use on Post-treatment Abstinence: A Randomized Controlled Trial”. Addiction. Wiley. doi:10.1111/add.14049.

Behavior ModificationJournal